Product Description
AMG 966 is a bi-specific, heteroimmunoglobulin molecule that binds both tumor necrosis factor alpha (TNFalpha) and TNF-like ligand 1A (TL1A). In a first-in-human clinical study in healthy volunteers, AMG 966 elicited anti-drug antibodies (ADA) in 53 of 54 subjects (98.1%), despite a paucity of T cell epitopes observed in T cell assays. ADA were neutralizing and bound to all domains of AMG 966. Development of ADA correlated with loss of exposure. In vitro studies demonstrated that at certain drug-to-target ratios, AMG 966 forms large immune complexes with TNFalpha and TL1A, partially restoring the ability of the aglycosylated Fc domain to bind Fcgamma RIa and Fcgamma RIIa, leading to the formation of ADA. (Sourced from: https://www.frontiersin.org/articles/10.3389/fimmu.2021.782788/full)
Mechanisms of Action: TNFa Inhibitor, TL1A Antagonist
Novel Mechanism: Yes
Modality: Bispecific Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Amgen
Company Location: Western America
Company Founding Year: 1980
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Colitis, Ulcerative|Crohn Disease
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|